GSK vs TEVA: stock comparison and AI forecast
Gsk Plc (GSK) and Teva Pharmaceutical Industries Ltd (TEVA) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
GSK Gsk Plc
- Price
- $48.70 -3.3% · 6M
- Market Cap
- $98.25B
- P/E Ratio
- 5.4x
- Size
- large-cap
- AI Forecast
TEVA Teva Pharmaceutical Industries Ltd
- Price
- $40.70 +15.1% · 6M
- Market Cap
- $48.84B
- P/E Ratio
- 40.3x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- GSK is 2.0 times larger than TEVA by market capitalization ($98.25B against $48.84B).
- GSK trades at 5.4 times trailing earnings, TEVA at 40.3 times.
- Over the last six months TEVA returned +15.1% and GSK -3.3%.
- TEVA carries 4.02 times debt per unit of equity, against 2.76 times for GSK.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | GSK | TEVA |
|---|---|---|
| Market Cap | $98.25B | $48.84B |
| P/E Ratio | 5.37x | 40.30x |
| P/B Ratio | – | 6.12x |
| EPS | $9.08 | $1.04 |
| Book Value/Share | – | $6.85 |
| Revenue/Share | $81.00 | $1.26 |
| FCF/Share | $15.23 | $1.06 |
Profitability & Margins
| Metric | GSK | TEVA |
|---|---|---|
| ROIC | – | 5.8% |
| Gross Margin | 70.8% | -444.2% |
| Operating Margin | 20.3% | 97.5% |
| EBT Margin | 18.2% | 59.2% |
| Tax Rate | 13.7% | -16.1% |
Financial Health
| Metric | GSK | TEVA |
|---|---|---|
| Current Ratio | 0.82x | 0.95x |
| Quick Ratio | 0.54x | 0.74x |
| D/E Ratio | 2.76x | 4.02x |
| Financial Leverage | – | 5.02x |
| Interest Coverage | – | 0.3x |
| Working Capital | -$5.23B | -$823M |
Cash Flow
| Metric | GSK | TEVA |
|---|---|---|
| Operating Cash Flow | $37.61B | $1.77B |
| Free Cash Flow | $30.73B | $1.24B |
| Capital Spending | -$6.88B | -$534M |
| OCF Growth YoY | -13.3% | 66.0% |
| FCF Growth YoY | 0.0% | 113.8% |
| FCF/Sales | 18.8% | 84.0% |
| CapEx/Sales | 4.2% | 36.3% |
Operational Efficiency
| Metric | GSK | TEVA |
|---|---|---|
| Asset Turnover | – | 0.04x |
| Receivables Turnover | 16.6x | 0.4x |
| Inventory Turnover | 6.1x | 2.5x |
| Fixed Assets Turnover | 13.3x | 0.4x |
| Days Sales Outstanding | 22 days | 951 days |
| Days Inventory | 60 days | 145 days |
| Payables Period | 155 days | – |
| Cash Conversion Cycle | -73 days | – |
Income Statement
| Metric | GSK | TEVA |
|---|---|---|
| Total Revenue | $163.43B | $1.47B |
| Operating Income | $33.20B | $1.44B |
| R&D Expense | $33.87B | $1.53B |
| SG&A Expense | $50.02B | $4.51B |
| Cost of Goods Sold | $47.81B | $8.01B |
Dividend & Shareholder Information
| Metric | GSK | TEVA |
|---|---|---|
| Shares Outstanding | 2017M | 1165M |
| EPS Growth | 87.6% | – |
GSK vs TEVA: stock comparison and AI forecast
Which is bigger, GSK or TEVA?
GSK is 2.0 times larger than TEVA by market capitalization ($98.25B against $48.84B).
Which is cheaper on earnings, GSK or TEVA?
GSK trades at 5.4 times trailing earnings, TEVA at 40.3 times.
Which stock performed better over the last six months, GSK or TEVA?
Over the last six months TEVA returned +15.1% and GSK -3.3%.
Which one does Intratio's AI model rank higher, GSK or TEVA?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.